Applied Therapeutics Inc (APLT) concluded trading on Thursday at a closing price of $0.59, with 3.96 million shares of worth about $2.34 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -90.36% during that period and on February 13, 2025 the price saw a gain of about 9.50%. Currently the company’s common shares owned by public are about 116.36M shares, out of which, 91.54M shares are available for trading.
Stock saw a price change of -2.71% in past 5 days and over the past one month there was a price change of -7.36%. Year-to-date (YTD), APLT shares are showing a performance of -30.78% which decreased to -78.98% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.54 but also hit the highest price of $10.62 during that period. The average intraday trading volume for Applied Therapeutics Inc shares is 7.04 million. The stock is currently trading -0.83% below its 20-day simple moving average (SMA20), while that difference is down -30.43% for SMA50 and it goes to -88.05% lower than SMA200.
Applied Therapeutics Inc (NASDAQ: APLT) currently have 116.36M outstanding shares and institutions hold larger chunk of about 80.16% of that.
The stock has a current market capitalization of $68.96M and its 3Y-monthly beta is at 1.87. It has Quick Ratio of 1.06 while making debt-to-equity ratio of 0.33. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for APLT, volatility over the week remained 10.23% while standing at 11.14% over the month.
Stock’s fiscal year EPS is expected to rise by 1.41% while it is estimated to increase by 58.08% in next year. EPS is likely to grow at an annualized rate of 41.84% for next 5-years, compared to annual growth of -8.72% made by the stock over the past 5-years.
Coverage by UBS stated Applied Therapeutics Inc (APLT) stock as a Neutral in their note to investors on December 02, 2024, suggesting a price target of $2 for the stock. Stock get an Outperform rating from RBC Capital Mkts on March 26, 2024.
